Download PDF
Int J Sports Med 2000; 21(7): 471-479
DOI: 10.1055/s-2000-7421
Physiology and Biochemistry
Georg Thieme Verlag Stuttgart · New York

Reticulocyte Parameters as Potential Discriminators of Recombinant Human Erythropoietin Abuse in Elite Athletes

R. Parisotto1 ,  C. J. Gore2 ,  A. G. Hahn1 ,  M. J. Ashenden1 ,  T. S. Olds3 ,  D. T. Martin1 ,  D. B. Pyne1 ,  K. Gawthorn1 ,  C. Brugnara4
  • 1 Department of Physiology and Applied Nutrition, Australian Institute of Sport, Canberra, Australia
  • 2 Australian Institute of Sport, Adelaide, Australia
  • 3 School of Physical Education and Sport Science, The University of South Australia, Adelaide, South Australia
  • 4 Departments of Pathology and Laboratory Medicine. The Children's Hospital, Harvard Medical School, Boston, MA, USA
Further Information

Publication History

Publication Date:
31 December 2000 (online)

Also available at
    Permissions and Reprints

This study investigated using reticulocyte (retic) parameters as indirect markers of human recombinant erythropoietin (r-HuEPO) abuse in elite athletes. Absolute reticulocyte count (# retic), the per cell haemoglobin content of reticulocytes (CHr), reticulocyte haemoglobin mass per litre of blood (RetHb) and red blood cell : reticulocyte haemoglobin (RBCHb : RetHb) ratio were assessed using flow cytometry. Venous blood was drawn from 155 elite athletes from six sports during regular training to establish reference ranges (95 % confidence interval) for these parameters. The reference ranges were compared with those of a non-athletic population (n = 23), four groups of athletes (n = 24) before and after exposure to simulated altitudes (2500 - 3000 m for 11 - 23 nights), two groups of elite cyclists (n = 13) before and after four weeks of training at natural altitude (1780 and 2690 m), and with those of non-athletic subjects from a separate study (n = 24) before and 1 - 2 days after they were injected with 1200 U × kg-1 r-HuEPO over a 9 - 10 day period. Generally the changes induced by r-HuEPO injection exceeded by approximately 100 % the magnitude of the changes associated with natural altitude exposure. Simulated altitude exposure did not significantly alter the reticulocyte parameters. From the sample of 155 non-users and 24 r-HuEPO users, the population mean and variance, as well as the 95 % confidence limits for the population mean and population variance, were estimated. Relative to arbitrarily chosen cut-off levels, the confidence limits for the rate of true positives and rate of true negatives were also calculated. Based on the lowest rate of false positives and highest rate of true positives, the best discriminator between r-HuEPO users and non-users was # retic, marginally superior to RBCHb : RetHb ratio and RetHb. At a cut-off for # retic of 221 × 109 × L-1 we could be 95 % sure that we would find no more than 7 false positives in every 100 000 tests. We would expect to pick up 51.8 % of users, and could be 95 % sure of picking up at least 38 % of current or recent users. This result highlights the potential power of retic parameters for detecting r-HuEPO abuse among athletes. However, the efficacy of these cut-offs for detecting r-HuEPO abuse is unknown if an athlete is a chronic user or stops using r-HuEPO several weeks before being tested.

Key words:

Reticulocyte parameters, elite athletes, altitude, erythropoietin.

References

  • 1 Ashenden M J, Parisotto R, Dobson G P, Hahn A G. Reticulocyte parameters can be obtained from capillary blood samples.  Aust J Med Sci. 1997;  18 78-83
    PubMedGoogle Scholar
  • 2 Audran M, Gareau R, Matecki S, Durand F, Chenard C, Sicart M T, Marion B, Bressolle F. Effects of erythropoietin administration in training athletes and possible indirect detection in doping control.  Med Sci Sports Exerc. 1999;  31 639-645
    PubMedGoogle Scholar
  • 3 Birkeland K I, Donike M, Ljungqvist A, Fagerhol M, Jensen J, Hemmersbach P, Oftebro H, Haug E. Blood sampling in doping control. First experiences from regular testing in athletics.  Int J Sports Med. 1997;  18 8-12
    PubMedGoogle Scholar
  • 4 Bressolle F, Audran M, Gareau R, Baynes R D, Guidicelli C, Gomeni R. Population pharmacodynamics for monitoring epoetin in athletes.  Clin Drug Invest. 1997;  14 233-242
    PubMedGoogle Scholar
  • 5 Breymann C, Bauer C, Major A, Zimmermann R, Gautschi K, Huch A, Huch R. Optimal timing of repeated rh-erythropoietin administration improves its effectiveness in stimulating erythropoiesis in healthy volunteers.  Br J Haematol. 1996;  92 295-301
    CrossrefPubMedGoogle Scholar
  • 6 Brien A, Harris R, Simon T. The effects of autologous infusion of 400 ml of red blood cells on selected haematological parameters and 1500 m race time in highly trained runners.  Bahrain Med Bull. 1989;  11 6-16
    PubMedGoogle Scholar
  • 7 Brugnara C, Colella G, Cremins J, Langley R C, Schneider T J, Rutherford C J, Goldberg M A. Effects of subcutaneous recombinant human erythropoiesis in normal subjects: development of decreased reticulocyte haemoglobin content and iron deficient erythropoiesis.  J Lab Clin Med. 1994;  123 660-667
    PubMedGoogle Scholar
  • 8 Brugnara C, Zelmanovic D, Sorette M, Ballas S K, Platt O. Reticulocyte hemoglobin. An integrated parameter for evaluation of erythropoietic activity.  Am J Clin Pathol. 1997;  108 133-142
    PubMedGoogle Scholar
  • 9 Buick F J, Gledhill N, Froese A B, Spriet L, Meyers E C. Effect of induced erythrocythemia on aerobic work capacity.  J Appl Physiol. 1980;  48 636-642
    PubMedGoogle Scholar
  • 10 Casoni I, Ricci G, Ballarin E, Borsetto C, Grazzi G, Guglielmini C, Manfredini F, Mazzoni G, Patracchini M, De Paoli Vitali E, Rigolin F, Bartalotta S, Franze G P, Masotti M, Conconi F. Hematological indices of erythropoietin administration in athletes.  Int J Sports Med. 1993;  14 307-311
    PubMedGoogle Scholar
  • 11 Celsing F, Svedenhag J, Pihlstedt P, Ekblom B. Effects of anaemia and stepwise-induced polycythaemia on maximal aerobic power in individuals with high and low haemoglobin concentrations.  Acta Physiol Scand. 1987;  129 47-54
    PubMedGoogle Scholar
  • 12 Choi D, Kim M, Park J. Erythropoietin: physico- and biochemical analysis.  J Chromatogr B Biomed Appl. 1996;  687 189-199
    PubMedGoogle Scholar
  • 13 Conconi F, Casoni I, Manfredini F, Mazzoni G, Grazzi G, Guglielmini C, Ballarin F, Borsetto C, Buzzoni D, Guerra G, Ricci G, Dapporto M, Rigolin F. Detection of erythropoietin administration in sports. Proceedings of the Second International Symposium on Drugs in Sport. Towards the use of blood samples in doping control?. Lillehammer, Norway; August 29 - 31, 1993
    Google Scholar
  • 14 Daniel W W. Biostatistics: a foundation for analysis in the health sciences. New York; John Wiley & Sons 1991 5th Edition: 160-162
    Google Scholar
  • 15 Ekblom B, Berglund B. Effect of erythropoietin administration on maximal aerobic power.  Scand J Med Sci Sports. 1991;  1 88-93
    PubMedGoogle Scholar
  • 16 Gareau R, Brisson G R, Ayotte C, Dube J, Caron C. Erythropoietin doping in athletes: possible detection through measurement of fibrinolytic products.  Thromb Haemost. 1992;  68 481-482
    PubMedGoogle Scholar
  • 17 Gareau R, Gagnon M G, Thellend C, Chenard C, Audran M, Chanal J L, Ayotte C, Brisson G R. Transferrin soluble receptor: a possible probe for detection of erythropoietin abuse by athletes.  Horm Metab Res. 1994;  26 311-312
    PubMedGoogle Scholar
  • 18 Gore C, Craig N, Hahn A, Rice A, Bourdon P, Lawrence S, Walsh C, Stanef T, Barnes P, Parisotto R, Martin D, Pyne D. Altitude training at 2690 m does not increase total haemoglobin mass or sea level V˙O2max in world champion track cyclists.  J Sci Med Sport. 1998;  1 156-170
    PubMedGoogle Scholar
  • 19 Gore C J, Hahn A G, Burge C M, Telford R D. V˙O2max and haemoglobin mass of trained athletes during high intensity training.  Int J Sports Med. 1997;  18 477-482
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Harrison M H. Effects of thermal stress and exercise on blood volume in humans.  Physiol Rev. 1985;  65 149-209
    CrossrefPubMedGoogle Scholar
  • 21 Hopkins W G. A new view of statistics. Internet Society for Sport Science. http://www.sportsci.org/resource/stats/ 1998
    Google Scholar
  • 22 Jacobs K, Shoemaker C, Rudersdorf R, Neill S D, Kaufman R J, Mufson A, Seehra J, Jones S S, Hewick R, Fritsch E F. Isolation and characterization of genomic and cDNA clones of human erythropoietin.  Nature. 1985;  313 806-810
    CrossrefPubMedGoogle Scholar
  • 23 Johnson D L, Farrell F X, Barbone F P, McMahon F J, Tullai J, Hoey K, Livnah O, Wrighton N C, Middleton S A, Loughney D A, Stura E A, Dower W J, Mulcahy L S, Wilson I A, Jolliffe L K. Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1.   Biochemistry. 1998;  37 3699-3710
    CrossrefPubMedGoogle Scholar
  • 24 Major A, Bauer C, Breymann C, Huch A, Huch R. rh-erythropoietin stimulates immature reticulocyte release in man.  Br J Haematol. 1994;  87 605-608
    PubMedGoogle Scholar
  • 25 Major A, Mathez-Loic F, Rohling R, Gautschi K, Brugnara C. The effect of intravenous iron on the reticulocyte response to recombinant human erythropoietin.  Br J of Haematol. 1997;  98 292-294
    PubMedGoogle Scholar
  • 26 Martin D T, Ashenden M, Boston T, Parisotto R, Pyne D B, Hahn A G. Blood testing cyclists to determine haematocrit levels: Attempts to deter doping with r-HuEPO. Canberra; Conference Proceedings, Science and Medicine in Sport 1997: 232-233
    Google Scholar
  • 27 Robertson R J, Gilcher R, Metz K F, Caspersen C J, Allison T G, Abbott R A, Skrinar G S, Krause J R, Nixon P A. Hemoglobin concentration and aerobic work capacity in women following induced erythrocythemia.  J Appl Physiol. 1984;  57 568-575
    PubMedGoogle Scholar
  • 28 Rutherford C J, Schneider T J, Dempsey H, Kirn D H, Brugnara C, Goldberg M A. Efficacy of different dosing regimens for recombinant human erythropoietin in a simulated perisurgical setting: the importance of iron availability in optimizing response.  Am J Med. 1994;  96 139-145
    CrossrefPubMedGoogle Scholar
  • 29 Souillard A, Audran M, Bressolle F, Gareau R, Duvallett A, Chanal J-L. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in athletes. Blood sampling and doping control.  Br J of Clin Pharmacol. 1996;  42 355-364
    CrossrefPubMedGoogle Scholar
  • 30 Spriet L L, Gledhill N, Froese A B, Wilkes D L. Effect of graded erythrocythemia on cardiovascular and metabolic responses to exercise.  J Appl Physiol. 1986;  61 1942-1948
    PubMedGoogle Scholar
  • 31 Wrighton N C, Balasubramanian P, Barbone F P, Kashyap A K, Farrell F X, Jolliffe L K, Barrett R W, Dower W J. Increased potency of an erythropoietin peptide mimetic through covalent dimerization.  Nat Biotechnol. 1997;  15 1261-1265
    PubMedGoogle Scholar

Robin Parisotto

Sports Haematology and Biochemistry Laboratory Australian Institute of Sport

PO Box 176 Belconnen, ACT 2616 Australia

Phone: Phone:+ 61 (2) 6214-1237

Fax: Fax:+ 61 (2) 6214-1603

Email: E-mail:robin.parisotto@ausport.gov.au

      >